



Overview:

Synarc’s medical image-analysis, subject-recruitment, and biochemical-marker services enable life-science industry clients to execute clinical trials accurately while decreasing the time, uncertainty, and cost of product development. Synarc has partnered with industry leaders to bring numerous leading compounds to market across a broad spectrum of therapeutic areas. Our services integrate critical aspects of clinical-trial design and execution, from protocol design and subject recruitment to regulatory liaison on behalf of our clients. Our expert radiologists and scientists are innovators in all aspects of medical imaging and biochemical markers in drug development, and have pioneered many methods used in today’s clinical trials.

Number of employees: ~600

Number of clinical trials: Over 200

Therapeutic Specialty Areas:

- **Cardiology/Neurovascular Disease**
- **Neurology**
- **Oncology**
- **Orthopedics**
- **Osteoarthritis**
- **Osteoporosis**
- **Rheumatoid Arthritis**

Website:

www.synarc.com

CEO:

Hervé Girsault, Chief Executive Officer

Mr.Girsault is responsible for strategic planning, goal setting and company operations.

He has extensive experience in business development and licensing in the pharmaceutical industry. Until July 2005, he held a number of senior positions at Novartis, including Senior Vice President and Global Head of Partnering and Out-Licensing at Novartis Pharma in Basel, Global Head of Business Development & Licensing for Novartis Consumer Health and General Manager of Novartis Consumer Health in Benelux.

Before joining Novartis, Hervé was the General Manager of Gerber Products Company in France from 1990 to 1995. He started his professional career with Coopers & Lybrand Management Consultants, culminating in the position of Director of the Food & HealthCare practices, based in Paris. He earned an MBA with Honors from Columbia Business School in New York and has a Masters degree from a leading business school in Paris.